Roivant Sciences (ROIV) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- −$0.33
- EPS estimate
- −$0.31
- EPS surprise
- −6.80%
- Revenue surprise
- −12.58%
- Revenue
- $1.4M
- Revenue estimate
- $1.6M
- Reported
- Aug 6, 2026
Roivant Sciences reported fiscal Q1 2027 results on August 6, 2026, with a loss of $0.33 per share. That was wider than the expected $0.31 loss, a 6.80% miss. Revenue was $1.4 million against a $1.6 million estimate. Compared with fiscal Q1 2026, the loss widened from $0.25 per share and revenue fell about 36% from $2.2 million.
Losses are the norm in the table, with four exceptions: profits of $6.03 per share in fiscal Q3 2024, $0.12 in Q1 2025, $0.23 in Q3 2025 and $0.28 in Q4 2026. The $6.03 quarter made fiscal 2024 profitable at $5.35 per share. The other complete years were losses: $1.40 in fiscal 2023, $0.25 in 2025 and $0.34 in 2026. Revenue is small and uneven. It peaked at $55.1 million in fiscal Q1 2025, totalled about $125 million in fiscal 2024 and fell to about $8.3 million in fiscal 2026. Revenue came in below estimates in each of the last six quarters. Roivant beat EPS estimates 13 times in 20 quarters.
Fiscal Q2 results came out between November 10 and November 15 in each of the past five years. That points to mid-November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Aug 6, 2026 | −$0.31 | −$0.33 | −6.80% | $1.4M | SEC |
| Q4 2026 | May 20, 2026 | −$0.29 | $0.28 | +196.51% | $2.5M | SEC |
| Q3 2026 | Feb 6, 2026 | −$0.30 | −$0.17 | +43.41% | $2.0M | SEC |
| Q2 2026 | Nov 10, 2025 | −$0.32 | −$0.20 | +36.87% | $1.6M | SEC |
| Q1 2026 | Aug 11, 2025 | −$0.25 | −$0.25 | −0.84% | $2.2M | SEC |
| Q4 2025 | May 29, 2025 | −$0.26 | −$0.29 | −10.06% | $7.6M | SEC |
| Q3 2025 | Feb 10, 2025 | −$0.25 | $0.23 | +190.95% | $9.0M | SEC |
| Q2 2025 | Nov 12, 2024 | −$0.25 | −$0.31 | −25.51% | $4.5M | SEC |
| Q1 2025 | Aug 8, 2024 | −$0.24 | $0.12 | +149.32% | $55.1M | SEC |
| Q4 2024 | May 30, 2024 | −$0.26 | −$0.19 | +28.14% | $28.9M | SEC |
| Q3 2024 | Feb 13, 2024 | −$0.31 | $6.03 | +2051.46% | $37.1M | SEC |
| Q2 2024 | Nov 13, 2023 | −$0.29 | −$0.26 | +8.78% | $37.1M | SEC |
| Q1 2024 | Aug 14, 2023 | −$0.28 | −$0.23 | +19.98% | $21.6M | SEC |
| Q4 2023 | Jun 28, 2023 | −$0.36 | −$0.22 | +39.43% | $27.4M | SEC |
| Q3 2023 | Feb 13, 2023 | −$0.39 | −$0.41 | −4.82% | $17.1M | SEC |
| Q2 2023 | Nov 14, 2022 | −$0.38 | −$0.29 | +22.73% | $12.5M | SEC |
| Q1 2023 | Aug 15, 2022 | −$0.32 | −$0.48 | −50.19% | $4.3M | SEC |
| Q4 2022 | Jun 28, 2022 | −$0.31 | −$0.27 | +11.38% | $9.2M | SEC |
| Q3 2022 | Feb 14, 2022 | −$0.25 | −$0.41 | −61.04% | $24.3M | SEC |
| Q2 2022 | Nov 15, 2021 | −$0.33 | −$0.32 | +1.57% | $14.0M | — |
Quarterly revenue
Frequently asked questions
When did Roivant Sciences (ROIV) last report earnings?
Roivant Sciences last reported on Aug 6, 2026, covering fiscal Q1 2027.
Did ROIV beat earnings estimates?
No. Roivant Sciences reported EPS of −$0.33 for Q1 2027 against a −$0.31 estimate — a 6.80% miss.
How much revenue did ROIV report last quarter?
Roivant Sciences reported $1.4M in revenue for Q1 2027, against a consensus estimate of $1.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.